Global Cell Free DNA Isolation and Extraction Market: Focus on 25 Country Analysis, Competitive Landscape, Applications (NIPT, Oncology, etc.), Product and Platform - Analysis and Forecast, 2018-2026
|発行||BIS Research Inc.||商品コード||648090|
|出版日||ページ情報||英文 335 Pages
|世界のセルフリーDNA分離・抽出市場の分析と予測：2018年～2026年 Global Cell Free DNA Isolation and Extraction Market: Focus on 25 Country Analysis, Competitive Landscape, Applications (NIPT, Oncology, etc.), Product and Platform - Analysis and Forecast, 2018-2026|
|出版日: 2018年06月04日||ページ情報: 英文 335 Pages||
The global cell free DNA isolation and extraction market is anticipated to grow over $442.8 Million with 14,638.3 Thousand units by 2026, aided by the rising demand for non-invasive prenatal testing among high risk pregnant women and increased demand for liquid biopsy.
Cell-free DNA are non-encapsulated DNA that enters the bloodstream during apoptosis or necrosis. This cell-free DNA is cleared by macrophages during normal body functioning, but overproduction of cells during cancer produces extra cfDNA in the blood. The CfDNA are found in blood, plasma, serum, or other body fluids and holds clinical significance in diagnosis, monitoring, and detection of various non-invasive diseases. The cfDNA is a screening method for tumors and other fetal DNA studies, they are challenging to extract as they are found in small quantities, and so reliable and consistent methods are required to isolate the less abundant cell-free DNA with higher sensitivity as they have a half-life of about two hours. The global cfDNA extraction and isolation industry is a multi-billion-dollar market which consists of multitudinous companies involved in the development of cfDNA extraction/isolation kits and automated instruments based on various sequencing platforms such as NGS and PCR to bolster the increasing demand for non-invasive screening tests and procedures.
cfDNA extraction and isolation products include extraction/isolation kit, automated instruments, and other consumables to improve the overall non-invasive screening process efficiency. Cell-free DNA testing is a new and efficient technology in which free-flowing DNA fragments from a liquid sample such as saliva, urine, and blood from patients are analyzed to screen a condition or disease. Cell-free DNA testing is essential solutions for the medical diagnostic companies that are facing increasing level of demand for high productivity and cost reduction. The recent advances in Cell-free DNA testing have paved the way for the development of multiple advanced technologies to aid in the battle against cancer and various other diseases including genetic and infectious diseases. The advent of screening procedures such as NIPT and liquid biopsy with improved efficiency of screening results are the most prominent factors facilitating the growth of Cell-free DNA testing in the medical diagnostic industry. Furthermore, these advanced testing procedures have also enabled the companies in the medical diagnostic industry to meet the regulatory compliance as well as manage their profit margins and remain competitive in the market.
The purpose of this study is to gain a holistic view of the Cell-free DNA testing market in terms of various influencing factors, such as recent trends and technological advancements. The scope of this report constitutes an in-depth study of the global Cell-free DNA testing market, including a thorough analysis of the products across different regions. The market has been segmented into ‘product', ‘platform', ‘application ‘and ‘regions'. The report presents the reader with an opportunity to unlock comprehensive insights concerning the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
This research report aims at answering various aspects of the global Cell-free DNA testing market with the help of the key factors driving the market, restraints that can inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities and challenges) and industry analysis as well.
The research study considers the market share analysis for a comprehensive understanding of the global Cell-free DNA testing market and assesses the factors governing the same. Growth share matrix and detailed pricing analysis have been included in the report. The market by region has been further sub-segmented into various countries, and in each sub-segment, the key market trends, list of the key players, and the recent developments that have taken place have been discussed.
The key players who have been contributing significantly to the Cell-free DNA testing market include: Agilent Technologies, Inc., Berry Genomics, BGI Diagnostics, BioCAT GmbH, F. Hoffmann-La Roche AG, GATC Biotech AG., Illumina, Inc., Laboratory Corporation of America, LifeCodexx AG, Merck KGaA, Natera Inc., NIPD Genetics, Norgen Biotek Corp., PreAnalytiX GmbH, Premaitha Health Plc, QIAGEN, Quest Diagnostics, SeraCare Life Sciences, Inc., STRATEC Biomedical AG, Thermo Fisher Scientific, AccuBioMed, Aline Biosciences, BioChain, Bioo Scientific Corporation, COVARIS, INC., Epigentek Group Inc., NeoGenStar LLC, Omega Bio-tek, Inc, Promega Corporation, System Biosciences, LLC., and STRECK, INC., among others.